## BEAM: Beam Therapeutics Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.2% in lower entry zone (3.0-6.0%), top 9% cross-sectional ranking. Short-term MRS_5 (3.5%) confirms momentum alignment. Strong momentum (+3.5% 5-day acceleration). Outperforming sector by 3.4%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($24.60)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy**
- Source: Insider Monkey | 20251222T120913 | Bullish | Relevance: 100%
- Beam Therapeutics (NASDAQ: BEAM) is considered an attractive investment due to promising data from its BEACON trial for sickle cell disease. H.C. Wainwright analyst Patrick Trucchio reaffirmed a Buy rating with an $80 target, citing the potential for risto-cel as an effective cure and the company's differentiated manufacturing process. The stock has received overwhelmingly positive analyst ratings, further supporting its potential.

**2. BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy**
- Source: Finviz | 20251222T120913 | Bullish | Relevance: 96%
- Beam Therapeutics (BEAM) is considered an attractive investment due to positive data from its BEACON trial, which indicates that risto-cel could be a unique and effective treatment for sickle cell disease. H.C. Wainwright analyst Patrick Trucchio has a bullish stance on the stock, projecting a significant upside. The company's differentiated manufacturing process for risto-cel further enhances its competitive edge in the ex vivo hematology space.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Evercore ISI Gr | $35 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Evercore ISI Gr | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.02M) |
| Sells | 5 ($0.65M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 2 |

**Top Holders:**
- FMR, LLC: 11.5% (-9.8%)
- ARK Investment Manag: 10.9% (+24.8%)
- Farallon Capital Man: 9.9% (+0.5%)
- Vanguard Group Inc: 9.1% (-4.7%)
- Blackrock Inc.: 8.0% (+1.8%)

### Key Risks

1. High beta (2.22) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Valuation stretched: PEG 7.1x requires aggressive growth execution.
3. High short interest (23.2%, 9.3 days to cover): squeeze risk or crowded bearish bet.

### Catalysts

- Momentum building: MRS_10 improving +3.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 7.09 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (6.0x), low leverage (D/E 0.36). Institutional flow bullish (6 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.8B |
| Beta | 2.22 |
| 52W Range | $13.53 - $35.25 |
| Short Interest | 23.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 7.09 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -0.3% to 3.2% (+3.5% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 91st percentile. MRS_5 at 3.5% confirms short-term momentum alignment. Outperforming sector by 3.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.21% (CS: 91) | Strong |
| RSI_14 | 60.2 | Neutral |
| MACD Histogram | 0.02 | Bullish |
| vs SMA20 | 1.065x | Above |
| vs SMA50 | 1.110x | Above |
| vs SMA200 | 1.330x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $27.92
- **Stop Loss:** $24.60 (11.9% risk)
- **Target:** $32.90 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 361
- **Position Value:** $10,079.12
- **Portfolio %:** 10.08%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-24 (Est: $-1.12)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.01 | $-1.10 | -8.9% |
| 2025Q2 | $-1.09 | $-1.00 | +8.4% |
| 2025Q1 | $-1.17 | $-1.24 | -5.9% |
| 2024Q4 | $-1.22 | $-1.09 | +10.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*